OC-30: POTENTIALITIES OF EXTRACTS FROM Solanaceae FAMILY AGAINST Leishmania amazonensis

J Pharm Pharmacogn Res 3(suppl. 1): S49, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Oral Communication

OC-30: POTENTIALITIES OF EXTRACTS FROM Solanaceae FAMILY AGAINST Leishmania amazonensis

Monzote L, Cuesta-Rubio O, Jimenez J, Quintino C, Márquez I, Gutiérrez Y, Wagner V.

Departamento de Parasitología, Instituto de Medicina Tropical “Pedro Kourí”, Apartado Postal 601, Marianao 13, La Habana, Cuba. Tel.: 53 7 202 5061; fax: 53 7 204 6051. E-mail: monzote@ipk.sld.cu

 

Introduction: Leishmaniasis is a disease caused by vector-borne protozoan parasites of the genus Leishmania. There is no human vaccine available and control disease relies mainly on treatment. Nevertheless, available drugs are toxic, expensive and not useful against all forms of disease. Therefore, urgent need for novel, effective, and safe drugs for treatment of leishmaniasis continue. Potentialities of plant derived-products have been extensive demonstrated against Leishmania parasite. In this study, we perform an in vitro assessment of 226 extracts of 12 genus and 46 species from family Solanaceae growing in Cuba and in vivo evaluation of promissory extracts. Metabolities profile was also determined. Material and Methods: Evaluation against promastigotes and intracellular amastigotes of L. amazonensis were performed; while cytotoxicity on peritoneal macrophage from BALB/c mice was also determined. Promissory extracts were tested on in vivo model of cutaneous leishmaniasis in Balb/c mice, which five doses were administer at 30 mg/kg every 4 days by intralesional route. A comparison of chemical profile of active extracts and probably bioactive constituents responsible of anti-leishmanial activity were also performed. Results: Eleven extracts (27.5%) from nine plants were selected as potential products in in vitro assay; while in animal model only Solanum havanense and S. myriacanthum were able to control diseases progression. Six compounds were identified from potential extracts. Conclusions: The results demonstrated the versatility of family Solanaceae and introduce preliminary pharmacological assay to motivate scientific community the searching of new anti-leishmanial agents in non-explore species of this family.

 

Citation Format: Monzote L, Cuesta-Rubio O, Jimenez J, Quintino C, Márquez I, Gutiérrez Y, Wagner V (2015) Potentialities of extracts from Solanaceae family against Leishmania amazonensis. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S49. Abstract nr OC-30.